Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival
about
Management of low-grade glioma.Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma.Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis.Insulin and glucagon regulate pancreatic α-cell proliferationMedical therapy of gliomas.A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.Ciliary transport regulates PDGF-AA/αα signaling via elevated mammalian target of rapamycin signaling and diminished PP2A activity.Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas.AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axisPTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcomeThe combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancerEpilepsy in patients with a brain tumour: focal epilepsy requires focused treatment.The molecular landscape of diffuse glioma and prospects for biomarker development.Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma.Glioblastoma: pathology, molecular mechanisms and markers.Epidermal growth factor-like module containing mucin-like hormone receptor 2 expression in gliomas.Antiproliferative effects of γ-secretase inhibitor, a Notch signalling inhibitor, in multiple myeloma cells and its molecular mechanism of action.Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors.mTORC1 signaling in primary central nervous system lymphoma.Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.Hypomethylation of CNTFRα is associated with proliferation and poor prognosis in lower grade gliomas.PRAS40 acts as a nodal regulator of high glucose-induced TORC1 activation in glomerular mesangial cell hypertrophy.TET1 exerts its tumour suppressor function by regulating autophagy in glioma cells.Phosphorylated ribosomal protein S6 correlation with p21 expression and inverse association with tumor size in oral squamous cell carcinoma.Functional network analysis of gene-phenotype connectivity associated with temozolomide.High LC3/Beclin Expression Correlates with Poor Survival in Glioma: a Definitive Role for Autophagy as Evidenced by In Vitro Autophagic Flux.Overexpression of mTOR and p(240-244)S6 in IDH1 Wild-Type Human Glioblastomas Is Predictive of Low Survival.Evaluation of Akt and RICTOR Expression Levels in Astrocytomas of All Grades.Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma.Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial.Cerebellar Ganglioglioma in Childhood: Histopathologic Implications for Management During Long-term Survival: A Case Report.Immunohistochemical evaluation of the mTOR pathway in intra-oral minor salivary gland neoplasms.Association between AKT/mTOR signalling pathway and malignancy grade of human gliomas.Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
P2860
Q30436353-32209624-2506-4A72-AE96-22C3CA516274Q33275031-4934930B-0907-483F-AFC7-6419436694D4Q33275157-D944E4F8-E7B6-4F3E-9847-94B24A7375FAQ33808713-37FEB58B-1AE4-4D4D-BF88-0A8FD8137028Q34218761-02EFB7D0-CB2C-4163-B4CE-370D8684E5F9Q34818301-FE188344-1F98-4472-A51B-05710DC39A5DQ34960781-027442D0-DB05-447E-B7CC-689FEDC9EA29Q35143738-DB397577-9CA1-44A6-960D-3E448C63436FQ35864082-EAC2D1FE-3851-461F-9A13-4F531886D152Q35987253-17C7C624-910F-4071-A272-D685EFB4C02BQ36179171-E0C497EC-3A69-483A-B754-FD9BA89EC9D0Q36833480-8E686954-4650-4DEB-A0B7-387D8978EA3AQ37636833-B8FFF103-DB52-4C27-8187-C76791577CBAQ37968607-1DB61A44-5628-4162-83ED-0BDE070F5C7AQ38155656-81F1445C-406B-4507-B112-18EA280FAF6BQ38408862-E4343B38-2A11-4A5C-BEFC-456FD1EDC400Q38460865-F6009F5A-5101-4869-A38B-BEFDF1C255D4Q38958545-0E3FCBB3-2FA6-4672-A8E4-815B1FF8603FQ39128267-FB0CAAA3-F570-4CD5-9C5C-709C7F3E60BBQ39365297-4F4E2477-BCAC-4BB8-B30F-2D3659B2C6AFQ39501076-F7535A55-9316-4C5E-B6B0-71C5FFAABDDEQ39593159-57715EFD-51F0-46A0-A378-3082444A481AQ40101428-8FE95D5C-19C8-4D3D-9B68-6B58A43B5875Q41204421-47DA294E-EA86-4F4F-BFA5-E331FC90B424Q42713697-38648889-861B-4E3B-9037-D4F770BB688DQ47129492-27F930E9-06A4-4102-97B6-FD3057E099C2Q47202432-C69FD65E-85D5-4EC5-A9D5-1D06D64D47EEQ47258480-B304F563-0AC2-4A73-9B7D-C78F51C14BD0Q47664663-3AC7CE1F-45FD-4B5E-B75C-A1D5333AB113Q47867724-AB2C3A89-EF60-45DE-AA43-457A30C378E2Q48450513-07B0A161-3977-4066-BCE1-2CCB719E0642Q48523422-DEA9AE02-25B4-43F5-A374-C7A9E9CEF55AQ48806296-EB057183-668A-4A03-B0DC-7F6BBCFE7D31Q50054743-71723AD5-DF70-4D24-A5DB-2FB9F3F0588EQ54194644-EB93A9B0-CF7F-430D-ABB4-DE2AB3AD9CBBQ54647171-D47DC7A2-F485-47E4-A64A-46BBF85549A2Q58731660-55D0D8F4-D8F8-47C6-A129-3BCE8E59B332
P2860
Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Activation of PI3K/mTOR pathwa ...... and predicts patient survival
@ast
Activation of PI3K/mTOR pathwa ...... and predicts patient survival
@en
type
label
Activation of PI3K/mTOR pathwa ...... and predicts patient survival
@ast
Activation of PI3K/mTOR pathwa ...... and predicts patient survival
@en
prefLabel
Activation of PI3K/mTOR pathwa ...... and predicts patient survival
@ast
Activation of PI3K/mTOR pathwa ...... and predicts patient survival
@en
P2093
P2860
P1476
Activation of PI3K/mTOR pathwa ...... and predicts patient survival
@en
P2093
Daniel A Perez
Daphne A Haas-Kogan
David Stokoe
John K Wiencke
Justin S Smith
Kathleen R Lamborn
Mei-Yin Polley
Michael D Prados
Mitchel S Berger
Scott R Vandenberg
P2860
P2888
P356
10.1007/S11060-009-0004-4
P577
2009-08-25T00:00:00Z
P5875
P6179
1036194195